However, the NIH Panel recommends against the use of systemic interferon beta for the treatment of hospitalized patients with COVID-19, against the use of interferon alfa or lambda for the treatment of hospitalized patients with COVID-19, except within a RCT, as well as against the use of interferons for the treatment of non-hospitalized patients with mild or moderate COVID-19, except within a RCT (COVID-19 Treatment Guidelines Panel, 2022). Here, IFNB1 is linked to COVID-19.